Vascular Effects of Sertraline in Heart Failure

This study has been terminated.
(PI change in institution)
Information provided by:
Yale University Identifier:
First received: December 22, 2007
Last updated: July 22, 2009
Last verified: July 2009
To determine the effects of chronic sertraline treatment on brachial artery flow-mediated dilation in patients with chronic heart failure and depression

Condition Intervention
Heart Failure
Drug: sertraline

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Effects of Chronic Sertraline Hydrochloride Administration on Vascular Endothelial and Autonomic Function in Patients With Chronic Heart Failure

Resource links provided by NLM:

Further study details as provided by Yale University:

Primary Outcome Measures:
  • Brachial artery flow-mediated dilation [ Time Frame: 2 months ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA
Plasma and serum

Enrollment: 4
Study Start Date: January 2006
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Chronic heart failure patients with concomitant depression
Drug: sertraline
open label 25-50 mg daily as tolerated


Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
chronic heart failure patients with concomitant depression

Inclusion Criteria:

  • Chronic heart failure with LVEF<40%, age >21 years
  • Depression requiring medical treatment with sertraline

Exclusion Criteria:

  • Known intolerance of sertraline
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00585455

United States, Connecticut
Yale University School of Medicine
New Haven, Connecticut, United States, 06510
Sponsors and Collaborators
Yale University
Principal Investigator: Stuart Katz, MD Yale School of Medicine
  More Information

No publications provided

Responsible Party: Stuart Katz, Yale University School of Medicine Identifier: NCT00585455     History of Changes
Other Study ID Numbers: 0410027131 
Study First Received: December 22, 2007
Last Updated: July 22, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by Yale University:
vascular endothelium
nitric oxide
heart failure
vascular biology

Additional relevant MeSH terms:
Heart Failure
Cardiovascular Diseases
Heart Diseases
Antidepressive Agents
Central Nervous System Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Uptake Inhibitors
Therapeutic Uses processed this record on February 11, 2016